Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Increased by Clarity Capital Partners LLC

Clarity Capital Partners LLC raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 21.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 11,142 shares of the medical research company’s stock after purchasing an additional 1,973 shares during the quarter. Clarity Capital Partners LLC’s holdings in Edwards Lifesciences were worth $825,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Alpha Financial Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $693,000. Koshinski Asset Management Inc. acquired a new position in Edwards Lifesciences in the third quarter worth approximately $396,000. Vontobel Holding Ltd. raised its position in Edwards Lifesciences by 5.7% during the third quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company’s stock valued at $28,977,000 after acquiring an additional 23,560 shares in the last quarter. nVerses Capital LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $792,000. Finally, Trust Co. of Vermont grew its position in Edwards Lifesciences by 36.1% in the third quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock worth $199,000 after acquiring an additional 801 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. The Goldman Sachs Group upped their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Robert W. Baird cut their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.71.

Edwards Lifesciences Stock Performance

EW opened at $75.83 on Thursday. The stock has a market cap of $44.72 billion, a PE ratio of 10.94, a P/E/G ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The stock’s 50 day simple moving average is $72.47 and its 200-day simple moving average is $69.32. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.